Stocks CNBC 1d ago

We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat

Market Intelligence Analysis

AI-Powered
Why This Matters

Eli Lilly's GLP-1 drugs have exceeded $1 billion in combined sales, with both Zepbound and Mounjaro showing triple-digit growth, leading to a raised price target.

Market Impact

Market impact analysis based on bullish sentiment with 90% confidence.

Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.

Continue Reading
Full article on CNBC
Read Full Article

Related Articles

Stocks 45m ago

Why Amazon’s CEO is ‘confident’ with $200 billion spending plan

Amazon has increased its 2026 capital expenditures to $200 billion, primarily allocating funds for data …
Stocks 4h ago

Crypto bill talks picking up in Senate after clearing a key vote, …

The US Senate is making progress on crypto legislation, with bipartisan efforts and industry involvement, …
Stocks 4h ago

Roblox shares rocket on earnings beat, strong forecast

Roblox shares experienced a significant increase of up to 20% in extended trading after the …
Stocks 56m ago

U.S.-China power struggle thrusts Panama Canal back into the spotlight

A recent court ruling in Panama has reignited tensions between the US and China, drawing …
Stocks 2h ago

CNBC Daily Open: Amazon's projected capex dwarfs that of its peers — …

Amazon's projected capital expenditure of $200 billion has exceeded analysts' estimates and surpassed its peers, …
Stocks 2h ago

Amazon learns a tough lesson in a market bailing on tech. Why …

Amazon's price target was lowered due to management's increased spending guide, indicating a potential slowdown …
Original article published by CNBC on February 4, 2026.
Analysis and insights provided by AnalystMarkets AI.